On the other hand, GLP1-RAs - namely dulaglutide, liraglutide, and semaglutide - have been proven to reduce the risk of major adverse cardiovascular outcomes with a neutral effect on heart failure [16-19]. The gene discussed is GLP1R; the disease is heart failure.